Hims & Hers Health, Inc.

Key metrics

Financial performance

Over the last 6 fiscal years Hims & Hers Health, Inc.'s revenue grew from $82.56M to $2.35B, a compound annual growth rate of 74.7%. Net profit margin expanded from -87.3% to 5.5% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (1,203 filings)

Recent press releases

• Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide2026-05-21

  _By introducing access to generic semaglutide in Canada, the company is meeting the needs of a dynamic market and continuing its international expansion efforts_

• Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results2026-05-11

  _Revenue of approximately $608 million, up 4% year-over-year in Q1 2026_

• Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors2026-04-28

  _If elected, the marketing leader from transformative companies like DoorDash and Meta will join a diverse board with medical, tech, and consumer expertise_

• Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 20262026-04-13

  The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year.

• Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers2026-03-26

  _Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight loss pill_

Similar companies

The largest companies sharing Hims & Hers Health, Inc.'s SEC industry classification (services-offices & clinics of doctors of medicine).